PHARMACOLOGICAL AND MORPHOLOGICAL FEATURES AND SOCIOECONOMIC ASPECTS OF CANNABIDIOL: A LITERATURE REVIEW
DOI:
https://doi.org/10.61751/ijmmr.2413-6077.2023.1.47Keywords:
cannabis, toxicology, law, epilepsy, chronic pain, generalised anxiety disorderAbstract
The relevance of detailed analysis of the available scientific research on the effects of cannabidiol on the human body is determined by the growing popularity of the non-psychoactive substance in cannabis products as a medicine. The research aimed to collect and systematise information about the positive and negative effects of cannabidiol, as well as the possibilities of its use in medicine. An analysis of 3375 scientific articles, publications and reports was conducted, of which 68 were selected that best met the terms of the request. The collected data was summarised and presented in a structured format. The results of the review indicate the remarkable pharmacological potential of cannabidiol, which can be used as a promising therapeutic agent in various medical fields. In the studies reviewed, cannabidiol showed anticonvulsant and antiepileptic effects, as well as a positive impact on drug substitution programmes. However, the possibility of negative reactions and potentially harmful effects of cannabidiol was also noted: it can lead to the development of psychological and physical dependence; increases the risk of physiological disorders, including the impact on spermatogenesis and disruption of the female microflora; affects behaviour and leads to developmental abnormalities. The effects of cannabidiol on the human body are still not well understood, and its distribution in the absence of sufficient legal regulation may pose a risk to the health and safety of consumers. Understanding all aspects of cannabidiol use will ensure proper management of its use and development of the relevant legislative framework, as well as facilitate further research and development of new drugs based on this plant extract
Received: 17.02.2023 | Revised: 26.04.2023 | Accepted: 30.05.2023
References
Zaychenko GV, Simonov PV. Medical cannabis and cannabinoids in clinical practice: Pharmacological effects and risks. Health Technol Assessm. 2019;2(2):13 –17. Available from: https://librarynmu.com/images/PDFfile/Zaichenko.pdf
Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol. 2019;176(10):138–94. DOI: 10.1111/bph.14426
Sulaieva O, Mashukov A, Kirkilevsky S. The tumour immune contexture and theranostic markers expression in patients with gastric carcinoma. Ann Oncol. 2020;31(Suppl 4):1115. DOI: 10.1016/j.annonc.2020.08.1300
Aliekperova N, Kosyachenko К, Kaniura O. Perspectives on formation of medical cannabis market in Ukraine based on holistic approach. J Cannabis Res. 2020;2:33. DOI: 10.1186/s42238-020-00044-y
Aliekperova N, Kostiuk I, Hala L, Biliaeva A. Pharmacists’ opinions on the legalization of medical cannabis in Ukraine. Research J. Pharm. and Tech. 2023;16(4):1851–56. DOI: 10.52711/0974-360X.2023.00303
Singh C, Rao K, Yadav N, Vashist Y, Chugh P, Bansal N, et al. Current cannabidiol safety: A review. Curr Drug Saf. 2023;18(4):465–73. DOI: 10.2174/1574886317666220902100511
Liu L, Liu J, Zhao M, Cai M, Lei F, Zeng X, Zhu B. A bibliometrics and visualization analysis of cannabidiol research from 2004 to 2021. Front Pharmacol. 2022;13:969883. DOI: 10.3389/fphar.2022.969883
Amin MR, Ali DW. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162:151–65. DOI: 10.1007/978-3-030-21737-2_8
Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J Am Chem Soc. 1940;62(1):196–200. DOI: 10.1021/ja01858a058
Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trials. Molecules. 2019;24(8):1459. DOI: 10.3390/molecules24081459
Parker LA, Rock EM, Mechoulam R. CBD: What Does the Science Say? [Internet]. Cambridge: The MIT Press; 2022 [cited 2023 Aug 17]. 320 p. DOI: 10.7551/mitpress/13686.001.0001
Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Della Pina S, et al. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019;224:120–27. DOI: 10.1016/j.lfs.2019.03.053
Raïch Iu, Rivas-Santisteban R, Lillo A, Lillo J, Reyes-Resina I, Nadal X, et al. Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors. Pharmacol Res. 2021;174:105970. DOI: 10.1016/j.phrs.2021.105970
Bosquez-Berger T, Gudorf JA, Kuntz CP, Desmond JA, Schlebach JP, VanNieuwenhze MS, Straiker A. Structure-activity relationship study of cannabidiol-based analogs as negative allosteric modulators of the μ-opioid receptor. J Med Chem. 2023;66(14):9466–94. DOI: 10.1021/acs.jmedchem.3c00061
Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019;74:282–98. DOI: 10.1016/j.neuro.2019.08.002
Martin LJ, Banister SD, Bowen MT. Understanding the complex pharmacology of cannabidiol: Mounting evidence suggests a common binding site with cholesterol. Pharmacol Res. 2021;166:105508. DOI: 10.1016/j.phrs.2021.105508
Khalsa JH, Bunt G, Blum K, Maggirwar SB, Galanter M, Potenza MN. Review: Cannabinoids as medicinals. Curr Addict Rep. 2022;9(4):630–46. DOI: 10.1007/s40429-022-00438-3
Luz-Veiga M, Azevedo-Silva J, Fernandes JC. Beyond pain relief: A review on cannabidiol potential in medical therapies. Pharmaceuticals. 2023;16(2):155. DOI: 10.3390/ph16020155
della Rocca G, Paoletti F, Conti MB, Galarini R, Chiaradia E, Sforna M, et al. Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs. Front Vet Sci. 2023;9:1104152. DOI: 10.3389/fvets.2022.1104152
Ruiz CM, Torrens A, Lallai V, Castillo E, Manca L, Martinez MX, et al. Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) THC in adolescent male and female rats. Psychopharmacology. 2021;238(12):3595–5. DOI: 10.1007/s00213-021-05976-8
Bardhi K, Coates S, Watson CJW, Lazarus P. Cannabinoids and drug metabolizing enzymes: Potential for drug-drug interactions and implications for drug safety and efficacy. Expert Rev Clin Pharmacol. 2022;15(12):1443–60. DOI: 10.1080/17512433.2022.2148655
Batinic A, Sutlovic D, Kuret S, Burcul F, Kalajzic N, Matana A, et al. Differences in plasma cannabidiol concentrations in women and men: A randomized, placebo-controlled, crossover study. Int J Mol Sci. 2023;24(12):10273. DOI: 10.3390/ijms241210273
Rao Q, Zhang T, Dai M, Li B, Pu Q, Zhao M, et al. Comparative metabolomic profiling of the metabolic differences of Δ9-tetrahydrocannabinol and cannabidiol. Molecules. 2022;27(21):7573. DOI: 10.3390/molecules27217573
Vlad RA, Hancu GH, Ciurba A, Antonoaea P, Rédai EM, Todoran N, et al. Cannabidiol – therapeutic and legal aspects. Pharmazie. 2020;75(10):463–69. DOI: 10.1691/ph.2020.0076
FDA. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) [Internet]. 2023 [cited 2023 Jul 15]. Available from: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
Chu W. Nutra Ingredients Europe. Updated EC Ruling for CBD as Novel Food [Internet]. 2019 [cited 2023 Jul 15]. Available from: https://www.nutraingredients.com/Article/2019/01/31/Updated-EC-ruling-for-CBD-classes-supplement-ingredient-as-Novel-Food
International Narcotics Control Board. Reports 2021 [Internet]. 2022 [cited 2023 Jul 15]. Available from: https://www.incb.org/documents/Publications/AnnualReports/AR2021/Annual_Report/E_INCB_2021_1_eng.pdf
Poperechna D. Medical cannabis usage has been legalized in Ukraine, but not entirely. Ukrainian Pravda [Internet]. 2021 Apr 9 [cited 2023 Jul 15]. Available from: https://life.pravda.com.ua/health/2021/04/9/244505/
Fortin D, Di Beo V, Massin S, Bisiou Y, Carrieri P, Barré T. Reasons for using cannabidiol: A cross-sectional study of French cannabidiol users. J Cannabis Res. 2021;3(1):46. DOI: 10.1186/s42238-021-00102-z
Gibbs B, Yates DA, Liebling J. CBD in the UK: Towards a responsible, innovative and high-quality cannabidiol industry. Centre for Medicinal Cannabis [Internet]. 2019 Jun [cited 2023 Jul 15]. 72 p. Available from: https://hempindustrydaily.com/wp-content/uploads/2020/04/Report-_-CBD-in-the-UK-002.pdf
Bisiou Y. Drugs, cannabis and cannabidiol (CBD): France under pressure from the CJEU. 2021. Available from: https://www.researchgate.net/publication/349454809_Stupefiants_cannabis_et_cannabidiol_CBD_la_France_sous_pression_de_la_CJUE
Dierking D. MJUS vs. MSOS: Which U.S. Cannabis market ETF looks better? ETF Focus. [Internet]. 2021 Jun 21 [cited 2023 Jul 15]. Available from: https://www.thestreet.com/etffocus/trade-ideas/mjus-msos-which-cannabis-etf-looks-better
Englund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, et al. Does cannabidiol make cannabis safer? A randomized, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacol. 2023;48(4):869–76. DOI: 10.1038/s41386-022-01478-z
Cannabidiol Global Market Report 2023. Report [Internet]. 2023 Feb [cited 2023 Jul 15]. 200 p. Available from: https://www.researchandmarkets.com/reports/5741562/cannabidiol-global-market-report
Kaufmann R, Harris Bozer A, Kube Jotte A, Aqua K. Long-Term, Self-Dosing CBD Users: Indications, dosage, and self-perceptions on general health/symptoms and drug use. Med Cannabis Cannabinoids. 2023;6(1):77–88. DOI:10.1159/000531666
Roser P, Habermeyer B, Scherbaum N, Lay B. Cannabidiol use among patients with substance use disorders. Subst Abuse Treat Prev Policy. 2022;17(1):59. DOI:10.1080/14659891.2022.2120425
Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: A systematic review. Alcohol Clin Exp Res. 2019;43(4):550–63. DOI: 10.1111/acer.13964
Vitale RM, Iannotti FA, Amodeo P. The (poly)pharmacology of cannabidiol in neurological and neuropsychiatric disorders: Molecular mechanisms and targets. Int J Mol Sci. 2021;22(9):4876. DOI: 10.3390/ijms22094876
Metz VG, da Rosa JLO, Rossato DR, Milanesi LH, Burger ME, Pase CS. Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats. Eur Neuropsychopharmacol. 2021;50. DOI: 10.1016/j.euroneuro
Nouri K, Anooshe M, Karimi-Haghighi S, Mousavi Z, Haghparast A. Involvement of hippocampal D1-like dopamine receptors in the inhibitory effect of cannabidiol on acquisition and expression of methamphetamine-induced conditioned place preference. Neurochem Res. 2021;46(8):2008-2018. DOI: 10.1007/s11064-021-03350-w
Rizkallah E, Mongeau-Pérusse V, Lamanuzzi L, Castenada-Ouellet SA, Stip E, Juteau LC, et al. Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacol Biochem Behav. 2022;216:173376. DOI: 10.1016/j.pbb.2022.173376
Qian Y, Gilliland TK, Markowitz JS. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin. Chem Biol Interact. 2020;316:108914. DOI: 10.1016/j.cbi.2019.108914
Brice-Tutt AC, Montgomery DS, Kramer CM, Novotny PM, Malphurs WL, Sharma A. An ethogram analysis of cutaneous thermal pain sensitivity and oxycodone reward-related behaviors in rats. Version 1. Res Sq [Preprint]. 2023. DOI: 10.21203/rs.3.rs-2679319/v1
Pallanti S, Marras A, Makris N. A research domain criteria approach to gambling disorder and behavioral addictions: Decision-making, response inhibition, and the role of cannabidiol. Front Psychiatry. 2021;12:634418. DOI: 10.3389/fpsyt.2021.634418
Madden K, Tanco K, Bruera E. Clinically significant drug-drug interaction between methadone and cannabidiol. Pediatrics. 2020;145(6):e20193256. DOI: 10.1542/peds.2019-3256
Darweesh RS, Khamis TN, El-Elimat T. The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(10):1871–86. DOI: 10.1007/s00210-020-01878-2
Stohs SJ, Ray D. Is cannabidiol hepatotoxic or hepatoprotective: A review. Toxicol Res Appl. 2020;4. DOI: 10.1177/2397847320922944
Flores VA, Kisiolek JN, Ramani A, Townsend R, Rodriguez E, Butler B, Stewart LK. Effects of oral cannabidiol on health and fitness in healthy adults: An 8-week randomized trial. Nutrients. 2023;15(12):2664. DOI: 10.3390/nu15122664
Matheson J, Bourgault Z, Le Foll B. Sex differences in the neuropsychiatric effects and pharmacokinetics of cannabidiol: A scoping review. Biomolecules. 2022;12(10):1462. DOI: 10.3390/biom12101462
Pandelides Z, Thornton C, Faruque AS, Whitehead AP, Willett KL, Ashpole NM. Developmental exposure to cannabidiol (CBD) alters longevity and health span of zebrafish (Danio rerio). GeroScience. 2020;42(2):785–800. DOI: 10.1007/s11357-020-00182-4
Carvalho RK, Rocha TL, Fernandes FH, Gonçalves BB, Souza MR, Araújo AA, et al. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: New insights of cannabidiol-mediated male reproductive toxicity. Chem Biol Interact. 2022;351:109743. DOI: 10.1016/j.cbi.2021.109743
Pandelides Z, Aluru N, Thornton C, Watts HE, Willett KL. transcriptomic changes and the roles of cannabinoid receptors and PPARγ in developmental toxicities following exposure to Δ9-tetrahydrocannabinol and cannabidiol. Toxicol Sci. 2021;182(1):44–59. DOI: 10.1093/toxsci/kfab046
Merrick J, Lane B, Sebree T, Yaksh T, O'Neill C, Banks SL. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis Cannabinoid Res. 2016;1(1):102–12. DOI: 10.1089/can.2015.0004
Henderson RG, Franke KS, Payne LE, Franzen A. Cannabidiol safety data: A systematic mapping study. Cannabis Cannabinoid Res. 2023;8(1):34–40. DOI: 10.1089/can.2022.0100
Reece AS, Hulse GK. Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: Part 3 – spatiotemporal, multivariable and causal inferential pathfinding and exploratory analyses of prostate and ovarian cancers. Arch Public Health. 2022;80(1):101. DOI: 10.1186/s13690-022-00813-6
Madera-Acosta A, Johnson-Wall H, Carbone LD, Meszaros A, Berman AE, White J. Cannabidiol (CBD) oil toxicity mimicking extraglandular complications of Sjögren's syndrome. Rheumatol Adv Pract. 2021;5(1):rkab010. DOI: 10.1093/rap/rkab010
Dellepiane S, Paranjpe I, Rajagopal M, Kamat S, O'Hagan R, Gulamali F, et al. Cannabis use and ckd: Epidemiological associations and mendelian randomization. Kidney med. 2022;5(2):100582. DOI: 10.1016/j.xkme.2022.100582
Carmona-Hidalgo B, García-Martín A, Muñoz E, González-Mariscal I. Detrimental effect of cannabidiol on the early onset of diabetic nephropathy in male mice. Pharmaceuticals (Basel). 2021;14(9):863. DOI: 10.3390/ph14090863
Mascal M, Hafezi N, Wang D, Hu Y, Serra G, Dallas ML, Spencer JP. Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures. Sci Rep. 2019;9(1):7778. DOI: 10.1038/s41598-019-44056-y
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (cbd): Toward a new age. Front Immunol. 2018;9:2009. DOI: 10.3389/fimmu.2018.02009
Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav. 2018;88:162–71. DOI: 10.1016/j.yebeh.2018.07.027
Hunter D, Oldfield G, Tich N, Messenheimer J, Sebree T. Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. J Osteoarthr Cartil. 2018;26(Suppl 1). DOI: 10.1016/j.joca.2018.02.067
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Knutsen HK, et al. Statement on safety of cannabidiol as a novel food: Data gaps and uncertainties. EFSA Journal. 2022;20(6):e07322. DOI: 10.2903/j.efsa.2022.7322
Dziwenka M, Coppock R, Davidson MH, Weder MA. Toxicological safety assessment of HempChoice® hemp oil extract; a proprietary extract consisting of a high concentration of cannabidiol (CBD) in addition to other phytocannabinoids and terpenes derived from Cannabissativa L. Heliyon. 2023;9(6):e16913. DOI: 10.1016/j.heliyon.2023.e16913
Sharifi A, Karimi-Haghighi S, Shabani R, Asgari HR, Ahadi R, Haghparast A. Cannabidiol impairs the rewarding effects of methamphetamine: Involvement of dopaminergic receptors in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry. 2022;113:110458. DOI: 10.1016/j.pnpbp.2021.110458
Mboumba Bouassa RS, Needham J, Nohynek D, Singer J, Lee T, Bobeuf F, et al. Safety and tolerability of oral cannabinoids in people living with hiv on long-term art: A randomized, open-label, interventional pilot clinical trial (CTNPT 028). Biomedicines. 2022;10(12):3168. DOI: 10.3390/biomedicines10123168
Rein JL. The nephrologist's guide to cannabis and cannabinoids. Curr Opin Nephrol Hypertens. 2020;29(2):248–57. DOI: 10.1097/MNH.0000000000000590
Sund LJ, Dargan PI, Archer JRH, Wood DM. E-cigarette or vaping-associated lung injury (EVALI): A review of international case reports from outside the United States of America. Clin Toxicol (Phila). 2023;61(2):91–97. DOI: 10.1080/15563650.2022.2160342
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Oles-Pylyp Hasiuk
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
